. Author manuscript; available in PMC: 2019 Mar 1.

Published in final edited form as: Mol Cancer Ther. 2018 Feb 14;17(3):698–709. doi: 10.1158/1535-7163.MCT-17-0552

Table 1.

Pharmacodynamic and antitumor response optimization for EMD1214063.

Treatment group	pY^1234/1235MET/MET at relevant time point (%)^a	No. of animals exhibiting given antitumor response^b
Treatment group	pY^1234/1235MET/MET at relevant time point (%)^a	PD	SD	PR	Total
vehicle (BID)	101.9 ± 48.6	8	0	0	8
3.125 mg/kg BID	46.7 ± 10.9	5	1	4	10
12.5 mg/kg BID	3.8 ± 3.9	0	3	7	10
50 mg/kg BID	0.4 ± 0.1	0	1	9	10
100 mg/kg QD	1.0 ± 0.5	0	0	10	10

Mean pY^1234/1235MET/MET values (± standard deviation) for the time point at which next dose was scheduled to be administered in the given dosage regimen (12 h for all groups except 100 mg/kg QD, for which the response at 24 h is shown). For pharmacodynamic data, n = 6 animals per group.

No.: number; PD: progressive disease; SD: stable disease; PR: partial response. Antitumor responses were designated according to RECIST criteria, comparing tumor volumes for each animal on the day prior to administration of the first dose vs. last day of tumor measurement (days 16 vs. 48, respectively): PD: ≥ 20% tumor volume increase; PR: ≥ 30% reduction in tumor volume; SD: tumor volume change between −30% and +20%.